Search Result

Results for "

BRD4 ligand

" in MedChemExpress (MCE) Product Catalog:

By Targets:	E3 Ligase Ligand-Linker Conjugates (17) PD-1/PD-L1 (1) Target Protein Ligand-Linker Conjugates (8) Apoptosis (6) Autophagy (1) ByeTAC (1) Drug Derivative (2) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) Epigenetic Reader Domain (103) Estrogen Receptor/ERR (1) FKBP (5) FLT3 (2) HIF/HIF Prolyl-Hydroxylase (1) Hippo (MST) (1) Histone Acetyltransferase (1) HIV (1) HSP (2) Hsp-targeting Chimeras (1) JAK (2) Ligands for E3 Ligase (8) Ligands for Target Protein for PROTAC (21) MDM-2/p53 (1) Molecular Glues (3) PROTAC-Linker Conjugates for PAC (1) PROTACs (66) Proteasome (1) Proteasome Cap Targeting Chimeras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (7)
By Research Areas:	Cancer (123) Infection (1) Inflammation/Immunology (3)
Click Chemistry:	PROTAC Synthesis (2) Azide (3) Tetrazine (1) Alkynes (4)

141

Inhibitors & Agonists

Click Chemistry

Targets Recommended: Target Protein Ligand-Linker Conjugates E3 Ligase Ligand-Linker Conjugates PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16954

ARV-825 Maximum Cited Publications 35 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
ARV-825 is a PROTAC connected by ligands for Cereblon and *BRD4. ARV-825 binds to BD1 and BD2 of BRD4* with K_ds of 90 and 28 nM, respectively.

HY-107425

MZ 1 20+ Cited Publications	PROTACs Epigenetic Reader Domain	Cancer
MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4* over BRD2 and BRD3. K_ds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively .

HY-101838

dBET1 15+ Cited Publications	PROTACs Epigenetic Reader Domain	Cancer
dBET1 is a PROTAC connected by ligands for Cereblon and *BRD4* with an EC₅₀ of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker .

HY-112609

QCA570	PROTACs Epigenetic Reader Domain	Cancer
QCA570 is a PROTAC connected by ligands for Cereblon and BET, with an IC₅₀ of 10 nM for BRD4 BD1 Protein.

HY-111433

BRD4 degrader AT1 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
BRD4 degrader AT1 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4* as a highly selective *Brd4* degrader, with a K_d of 44 nM for Brd4 ^BD2 in cells.

HY-114305

A1874 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
A1874 is a nutlin-based (MDM2 ligand) and *BRD4*-degrading PROTAC with a DC₅₀ of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation .

HY-114407

TD-428	PROTACs Epigenetic Reader Domain	Cancer
TD-428 is a PROTAC connected by ligands for Cereblon and *BRD4. TD-428 is a highly specific BRD4* degrader with a DC₅₀ of 0.32 nM . TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation .

HY-129939

BET-IN-31	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
BET-IN-31 is a potent BET inhibitor and a ligand for target *BRD4* protein for PROTACT GNE-987 (HY-129937A) .

HY-133131

PROTAC BRD4 Degrader-1	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and *BRD4* with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression .

HY-112375

AT6	PROTACs	Cancer
AT6 is a PROTAC AT1 analogue, which is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4* with highly selectivity to bromodomain (Brd4).

HY-112718

PROTAC BET Degrader-10	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-10 (dBET37) is a potent BET protein *BRD4* degrader, connected by ligands for Cereblon and *BRD4, with a DC₅₀* of 49 nM .

HY-112376

MZP-54 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
MZP-54 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD3/4, with a K_d* of 4 nM for Brd4 ^BD2.

HY-112429

HJB97 2 Publications Verification	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
HJB97 is a high-affinity BET inhibitor with K_i values of 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), and 1.0 nM (BRD4 BD2) . HJB97 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC BET degraders with antitumor activity . HJB97 can be used for the synthesis of BETd-260 (HY-101519).

HY-131387

(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 can be used in PROTAC BRD4 Degrader-5 (HY-133737) and PROTAC BRD4 Degrader-5-CO-PEG3-N3 (HY-133736) .

HY-161651A

BRD4 ligand 6 TFA	Epigenetic Reader Domain	Cancer
BRD4 ligand 6 TFA is the TFA salt form of BRD4 ligand 6 (HY-161651). BRD4 ligand 6 TFA is a *BRD4* ligand and can be used for synthesis of BRD4 PROTACs, such as PROTAC BRD4 Degrader-26 (HY-161650) .

HY-133136

PROTAC BRD4 Degrader-2	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and *BRD4* with an IC₅₀ of 14.2 nM against BRD4 BD1 .

HY-138555

PROTAC BRD4 Degrader-8	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4, with IC₅₀s of 1.1 nM and 1.4 nM for BRD4* BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .

HY-138632

PROTAC BRD4 Degrader linker conjugate	PROTACs Epigenetic Reader Domain PROTAC-Linker Conjugates for PAC	Cancer
PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of *BRD4* that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC₅₀ values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) .\n

HY-133737

GAL-02-221 PROTAC BRD4 Degrader-5	PROTACs Epigenetic Reader Domain	Cancer
GAL-02-221 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4. GAL-02-221 can potent degrade BRD4* in HER2 positive and negative breast cancer cell lines .

HY-112398

GSK1379725A	Epigenetic Reader Domain	Others
GSK1379725A is a selective BPTF ligand with a K_d of 2.8 uM, showing no binding activity for Brd4 .

HY-153459

IBG1	Molecular Glues Epigenetic Reader Domain	Cancer
IBG1 is a molecular glue degrader targeting *BRD2* and *BRD4* (DC₅₀: 0.15 nM). IBG1 has no significant degradation effect on its paralogue *BRD3. IBG1 can inhibit the growth of cancer cells and can be used in tumor research. (Pink: BRD2/BRD4* Ligand (HY-111139); Black: Linker; Blue: DCAF15 ligand-1 (HY-W037495)) .

HY-103633

PROTAC BET Degrader-1 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-1 is a PROTAC connected by ligands for Cereblon and BET, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.

HY-107442

PROTAC BRD4-binding moiety 1	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136) . PROTAC BRD4-binding moiety 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-133138

Pomalidomide-PEG1-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG1-azide is an E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-PEG1-azide can be used to synthesis PROTAC BRD4 Degrader-1 (HY-133131) . PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression.

HY-164995

L1BC8	PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC	Cancer
L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .

HY-112377

MZP-55 1 Publications Verification	Epigenetic Reader Domain PROTACs	Cancer
MZP-55 is a PROTAC connected by ligands for von Hippel-Lindau and *BRD3/4, with a K_d* of 8 nM for Brd4 ^BD2.

HY-174996

NEP162	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
NEP162 is a BRD4 PROTAC degrader with DC₅₀s of 1.2 and 1.6 μM in SW480 and U2OS cells. NEP162 exhibits antiproliferative activity, effectively inhibits tumor growth and induces apoptosis. NEP162 can be used for the study of osteosarcoma, colorectal cancer and non-small cell lung cancer, etc. (Pink: BRD4 ligand : (HY-78695), Blue: E3 ligase Ligand (HY-D2259), BLACK: Linker, E3 ligase ligand-linker conjugate (HY-174997)) .

HY-161651

BRD4 ligand 6	Epigenetic Reader Domain	Cancer
BRD4 ligand 6 is a *BRD4* ligand and can be used for synthesis of BRD4 PROTACs, such as PROTAC BRD4 Degrader-26 (HY-161650) .

HY-132942A

*PROTAC BRD4* ligand-2 hydrochloride**	Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD4 ligand-2 hydrochloride is a ligand for target BRD4 protein for PROTAC CFT-2718.

HY-176369

*PROTAC BRD4* ligand-1-NH-PEG-phenol-PEG-COOtBu**	Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain	Cancer
PROTAC BRD4 ligand-1-NH-PEG-phenol-PEG-COOtBu is an *Target Protein Ligand-Linker Conjugate* that incorporates a ligand for *BRD4* and a PROTAC linker. PROTAC BRD4 ligand-1-NH-PEG-phenol-PEG-COOtBu can be used for synthesis of PROTAC BRD4 Degrader-14 (HY-138637) .

HY-175242

*PROTAC BRD4* ligand-4**	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Others
PROTAC BRD4 ligand-4 is a *BRD4* ligand, which can be used to synthesize PROTAC BRD4 Degrader-37 (HY-175225) .

HY-174812

BRD4 ligand 8	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Inflammation/Immunology Cancer
BRD4 ligand 8 (Compound J558) is a *BRD4* inhibitor. BRD4 ligand 8 can be used for synthesis of PROTAC BRD4 Degrader-33 (HY-174811) .

HY-132942

*PROTAC BRD4* ligand-2**	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
PROTAC BRD4 ligand-2 is a ligand for target BRD4 protein for PROTAC CFT-2718.

HY-174210

PROTAC BRD4 Degrader-31	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-31 is a *BRD4* PROTAC degrader with DC₅₀ s of 164 and 80 nM at 4 h and 24 h, respectively. PROTAC BRD4 Degrader-31 potently degrades BRD4 in cells with long acting degradation kinetics . Pink: BRD4 ligand (HY-78695); Blue: KLHDC2 ligand (HY-174218)

HY-132130

BRD4 Inhibitor-13	Epigenetic Reader Domain	Inflammation/Immunology Cancer
BRD4 Inhibitor-13 (Compound 2) is a *BRD4* ligand, and can be used for research of cancer, inflammation.

HY-169358

L134	PROTACs Epigenetic Reader Domain	Cancer
L134 is a potent PROTAC BRD4 degrader with a DC₅₀ value of 7.36 nM. L134 mediates the degradation of BRD4 via the ubiquitin-proteasome system in a DCAF11-dependent manner (Blue: JQ-1 (carboxylic acid) (HY-78695), Black: linker (HY-W004640); Pink: E3 ligase ligand, L321 (HY-169359)) .

HY-42429

CPI-203-PEG1-C3-O-COOH	Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain	Cancer
CPI-203-PEG1-C3-O-COOH is a conjugate of the BRD4 ligand (HY-78695) and the linker (HY-42427). CPI-203-PEG1-C3-O-COOH can be used for synthesizing PROTAC BRD4 degrader ARV-771 (HY-100972) .

HY-132943

BRD4 ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates	Cancer
BRD4 ligand-Linker Conjugate 1 is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs.

HY-132991

ML 2-14 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
ML 2-14 is a PROTAC targeting *BRD4* with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219 (HY-115715) (bule part), the target protein ligand JQ-1 (HY-13030) (red part), and the PROTAC linker (balck part). ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells, and this effect can be reversed by the proteasome inhibitor Bortezomib (HY-10227) and the E1 activase inhibitor TAK-243 (HY-100487) .

HY-132943A

BRD4 ligand-Linker Conjugate 1 TFA	Target Protein Ligand-Linker Conjugates	Cancer
BRD4 ligand-Linker Conjugate 1 TFA (compound 106-1) is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs .

HY-162876

*PROTAC BRD4* ligand-3**	Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD4 ligand-3 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). PROTAC BRD4 ligand-3 can be used for synthesis PROTAC BRD4 Degrader-27 (HY-162875) .

HY-175224

PROTAC BRD4 Degrader-36	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-36 is a BRD4 PROTAC degrader. PROTAC BRD4 Degrader-36 has a DC₅₀ of 0.649 nM and a D_max of 71% in PANC-1 cells. PROTAC BRD4 Degrader-36 is cytotoxic to PANC-1 cells (GI₅₀: 0.103 μM). PROTAC BRD4 Degrader-36 can be used in the study of cancer. (Pink: PROTAC BRD4 ligand-1 (HY-129939); Blue + Black: E3 ligase ligand + linker (HY-175241)) .

HY-130612

PROTAC BRD2/BRD4 degrader-1	Epigenetic Reader Domain PROTACs	Cancer
PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein *BRD4* and *BRD2* degrader, connected by ligands for Cereblon and BET. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. It effectively inhibits solid tumors with low cytotoxic effect. PROTAC BRD2/BRD4 degrader-1 is composed of the BET inhibitor, a linker, and the ligand thalidomide for cereblon (CRBN)/cullin 4A .

HY-107425B

cis-MZ 1 hydrate	Epigenetic Reader Domain	Cancer
cis-MZ 1 hydrate is a negative control for *BRD4*-targeted PROTAC MZ 1 (HY-107425). cis-MZ 1 or MZ 1 is a combination of the von Hippel-Lindau ligand (red part in the structural formula) and the BRD4 ligand (blue part in the structural formula). The K_d of MZ 1 for BRD4 BD1/2 was 382 nM and 120 nM, respectively .

HY-174811

PROTAC BRD4 Degrader-33	PROTACs Epigenetic Reader Domain PD-1/PD-L1	Inflammation/Immunology Cancer
PROTAC BRD4 Degrader-33 is an enzyme activated clickable *BRD4* PROTAC degrader with favorable tumor microenvironment-response. PROTAC BRD4 Degrader-33 has superior tumor tissue penetration capabilities and efficiently inhibits PD-L1 protein expression. PROTAC BRD4 Degrader-33 shows potent anti-tumoral immunomodulation activity in 4T1 tumor-bearing mice model . Pink: BRD4 ligand (HY-174812); Blue: CRBN ligase ligand (HY-10984); Black: linker

HY-176502

FKBP12 ligand-3	FKBP	Cancer
FKBP12 ligand-3 (compound dj) is a high-affinity ligand targeting FKBP12. FKBP12 ligand-3 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP12 ligand-3 can be used for selective cancer research based on differences in intracellular presenter protein levels .

HY-130813

BET-IN-6	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BET-IN-6 is a potent and high affnity *BRD2/BRD4* inhibitor. BET-IN-6 is the *ligand* for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612) .

HY-139620

MS83	PROTACs	Cancer
MS83 is a proof-of-concept PROTAC by linking the KEAP1 ligand to a BRD4/3/2 binder.

HY-180152

BRD4 ligand 14	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BRD4 ligand 14 (Compound Y47) is a *BRD4* inhibitor. BRD4 ligand 14 exhibits mild anticancer properties against acute myeloid leukemia by inhibiting BRD4. BRD4 ligand 14 can also be used as a ligand for target protein for PROTAC in the development and design of PROTAC BRD4 degraders, such as PROTAC BRD4 Degrader-42 (HY-180150) .

HY-177730

PROTAC BRD4 Degrader-40	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-40 is a Bromodomain protein 4 (BRD4) PROTAC degrader. PROTAC BRD4 Degrader-40 can induce BRD4 degradation in cancer cells. PROTAC BRD4 Degrader-40 can be used for the research of cancer, such as leukemia . (Structure Note: Pink: BRD4 ligand (HY-78695); Blue: CRBN ligand (HY-163927))

Cat. No.	Product Name		Classification

HY-174995

JQ-1-Azidopropylamine		Azide
JQ-1-Azidopropylamine is an *Target Protein Ligand-Linker Conjugate* that incorporates a ligand for *BRD4* (HY-78695) and a PROTAC linker (HY-151862), which recruits E3 ligases. JQ-1-Azidopropylamine can be used for synthesis of PROTAC JY-21 (HY-174975) .

HY-133139

Lenalidomide-PEG1-azide		Azide PROTAC Synthesis
Lenalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker.?Lenalidomide-PEG1-azide?can be used to design a PROTAC BRD4 Degrader-2 (HY-133136) . Lenalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-107442

PROTAC BRD4-binding moiety 1		Alkynes
PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136) . PROTAC BRD4-binding moiety 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-133138

Pomalidomide-PEG1-azide		Azide PROTAC Synthesis
Pomalidomide-PEG1-azide is an E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-PEG1-azide can be used to synthesis PROTAC BRD4 Degrader-1 (HY-133131) . PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression.

HY-101460

Tz-Thalidomide		Tetrazine
Tz-Thalidomide is a tetrazine-tagged Thalidomide (HY-14658), an E3 ligase ligand. Tz-Thalidomide self-assembles with TCO-labeled target protein inhibitors, forming a CLIP-TAC (targeted protein degradation chimera) via click chemistry. This chimera recruits the E3 ubiquitin ligase CRBN to the target protein, thereby inducing ubiquitination and subsequent degradation of the target protein. When used in combination with JQ1-TCO (HY-148864), Tz-Thalidomide induces concentration-dependent degradation of *BRD4* in cells. When combined with ERK-targeting protein inhibitors, Tz-Thalidomide induces degradation of ERK1/2 in cells. Tz-Thalidomide can be used in cancer-related research .

HY-176502

FKBP12 ligand-3		Alkynes
FKBP12 ligand-3 (compound dj) is a high-affinity ligand targeting FKBP12. FKBP12 ligand-3 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP12 ligand-3 can be used for selective cancer research based on differences in intracellular presenter protein levels .

HY-182371

BRD4 ligand 15		Alkynes
BRD4 ligand 15 (compound 5) is a *BRD4* ligand and alkyne-modified chalcone derivative, which serves as a building block for the synthesis of *BRD4*-targeting PROTAC TKP-5 (HY-182370) .

HY-176501

FKBP12 ligand-2		Alkynes
FKBP12 ligand-2 (compound d) is a high affinity ligand targeting FKBP12. FKBP12 ligand-2 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP12 ligand-2 can be used for selective cancer research based on differences in intracellular presenter protein levels .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: